Breaking News
May 3, 2019 - Vaping and Smoking May Signal Greater Motivation to Quit
May 3, 2019 - Dementia looks different in brains of Hispanics
May 3, 2019 - Short-Staffed Nursing Homes See Drop In Medicare Ratings
May 3, 2019 - Study of teens with eating disorders explores how substance users differ from non-substance users
May 3, 2019 - Scientists develop new video game that may help in the study of Alzheimer’s
May 3, 2019 - Arc Bio introduces Galileo Pathogen Solution product line at ASM Clinical Virology Symposium
May 3, 2019 - Cornell University study uncovers relationship between starch digestion gene and gut bacteria
May 3, 2019 - How to Safely Use Glucose Meters and Test Strips for Diabetes
May 3, 2019 - Anti-inflammatory drugs ineffective for prevention of Alzheimer’s disease
May 3, 2019 - Study tracks Pennsylvania’s oil and gas waste-disposal practices
May 3, 2019 - Creating a better radiation diagnostic test for astronauts
May 3, 2019 - Vegans are often deficient in these four nutrients
May 3, 2019 - PPDC announces seed grants to develop medical devices for children
May 3, 2019 - Study maps out the frequency and impact of water polo head injuries
May 3, 2019 - Research on Reddit identifies risks associated with unproven treatments for opioid addiction
May 3, 2019 - Good smells may help ease tobacco cravings
May 3, 2019 - Medical financial hardship found to be very common among people in the United States
May 3, 2019 - Researchers develop multimodal system for personalized post-stroke rehabilitation
May 3, 2019 - Study shows significant mortality benefit with CABG over percutaneous coronary intervention
May 3, 2019 - Will gene-editing of human embryos ever be justifiable?
May 3, 2019 - FDA Approves Dengvaxia (dengue vaccine) for the Prevention of Dengue Disease in Endemic Regions
May 3, 2019 - Why Tonsillitis Keeps Coming Back
May 3, 2019 - Fighting the opioid epidemic with data
May 3, 2019 - Maggot sausages may soon be a reality
May 3, 2019 - Deletion of ATDC gene prevents development of pancreatic cancer in mice
May 2, 2019 - Targeted Therapy Promising for Rare Hematologic Cancer
May 2, 2019 - Alzheimer’s disease is a ‘double-prion disorder,’ study shows
May 2, 2019 - Reservoir bugs: How one bacterial menace makes its home in the human stomach
May 2, 2019 - Clinical, Admin Staff From Cardiology Get Sneak Peek at Epic
May 2, 2019 - Depression increases hospital use and mortality in children
May 2, 2019 - Vicon and NOC support CURE International to create first gait lab in Ethiopia
May 2, 2019 - Researchers use 3D printer to make paper organs
May 2, 2019 - Viral infection in utero associated with behavioral abnormalities in offspring
May 2, 2019 - U.S. Teen Opioid Deaths Soaring
May 2, 2019 - Opioid distribution data should be public
May 2, 2019 - In the Spotlight: “I’m learning every single day”
May 2, 2019 - 2019 Schaefer Scholars Announced
May 2, 2019 - Podcast: KHN’s ‘What The Health?’ Bye-Bye, ACA, And Hello ‘Medicare-For-All’?
May 2, 2019 - Study describes new viral molecular evasion mechanism used by cytomegalovirus
May 2, 2019 - SLU study suggests a more equitable way for Medicare reimbursement
May 2, 2019 - Scientists discover first gene involved in lower urinary tract obstruction
May 2, 2019 - Researchers identify 34 genes associated with increased risk of ovarian cancer
May 2, 2019 - Many low-income infants receive formula in the first few days of life, finds study
May 2, 2019 - Global study finds high success rate for hip and knee replacements
May 2, 2019 - Taking depression seriously: What is it?
May 2, 2019 - With Head Injuries Mounting, Will Cities Put Their Feet Down On E-Scooters?
May 2, 2019 - Scientists develop small fluorophores for tracking metabolites in living cells
May 2, 2019 - Study casts new light into how mothers’ and babies’ genes influence birth weight
May 2, 2019 - Researchers uncover new brain mechanisms regulating body weight
May 2, 2019 - Organ-on-chip systems offered to Asia-Pacific regions by Sydney’s AXT
May 2, 2019 - Adoption of new rules drops readmission penalties against safety net hospitals
May 2, 2019 - Kids and teens who consume zero-calorie sweetened beverages do not save calories
May 2, 2019 - Improved procedure for cancer-related erectile dysfunction
May 2, 2019 - Hormone may improve social behavior in autism
May 2, 2019 - Alzheimer’s disease may be caused by infectious proteins called prions
May 2, 2019 - Even Doctors Can’t Navigate Our ‘Broken Health Care System’
May 2, 2019 - Study looks at the impact on criminal persistence of head injuries
May 2, 2019 - Honey ‘as high in sugars as table sugar’
May 2, 2019 - Innovations to U.S. food system could help consumers in choosing healthy foods
May 2, 2019 - FDA Approves Mavyret (glecaprevir and pibrentasvir) as First Treatment for All Genotypes of Hepatitis C in Pediatric Patients
May 2, 2019 - Women underreport prevalence and intensity of their own snoring
May 2, 2019 - Concussion summit focuses on science behind brain injury
May 2, 2019 - Booker’s Argument For Environmental Justice Stays Within The Lines
May 2, 2019 - Cornell research explains increased metastatic cancer risk in diabetics
May 2, 2019 - Mount Sinai study provides fresh insights into cellular pathways that cause cancer
May 2, 2019 - Researchers to study link between prenatal pesticide exposures and childhood ADHD
May 2, 2019 - CoGEN Congress 2019: Speakers’ overviews
May 2, 2019 - A new strategy for managing diabetic macular edema in people with good vision
May 2, 2019 - Sagent Pharmaceuticals Issues Voluntary Nationwide Recall of Ketorolac Tromethamine Injection, USP, 60mg/2mL (30mg per mL) Due to Lack of Sterility Assurance
May 2, 2019 - Screen time associated with behavioral problems in preschoolers
May 2, 2019 - Hormone reduces social impairment in kids with autism | News Center
May 2, 2019 - Researchers synthesize peroxidase-mimicking nanozyme with low cost and superior catalytic activity
May 2, 2019 - Study results of a potential drug to treat Type 2 diabetes in children announced
May 2, 2019 - Multigene test helps doctors to make effective treatment decisions for breast cancer patients
May 2, 2019 - UNC School of Medicine initiative providing unique care to dementia patients
May 2, 2019 - Nestlé Health Science and VHP join forces to launch innovative COPES program for cancer patients
May 2, 2019 - Study examines how our brain generates consciousness and loses it during anesthesia
May 2, 2019 - Transition Support Program May Aid Young Adults With Type 1 Diabetes
May 2, 2019 - Study shows how neutrophils exacerbate atherosclerosis by inducing smooth muscle-cell death
May 2, 2019 - Research reveals complexity of how we make decisions
MTN launches new study to empower teen girls with choices in HIV prevention

MTN launches new study to empower teen girls with choices in HIV prevention

AIDS is already the leading cause of death among girls and young women in much of Africa, and matters could only get worse, given that for every day that passes, 1,000 more girls ages 15 to 24 are likely to become infected with HIV.

Ensuring that women and girls can have access to and benefit from safe and effective methods of prevention is imperative, say researchers from the National Institutes of Health (NIH)-funded Microbicide Trials Network (MTN) who have launched a new study called REACH and enrolled its first participant.

In REACH (Reversing the Epidemic in Africa with Choices in HIV prevention), or MTN-034, researchers are focusing on two methods they believe could make a difference for many young women – a daily oral tablet called Truvada®, an approach often referred to as PrEP, short for pre-exposure prophylaxis, which is now approved in many countries; and a monthly vaginal ring containing an antiretroviral (ARV) drug called dapivirine currently undergoing regulatory review.

If approved, the dapivirine ring would be the first biomedical prevention method specifically for women, i.e., for women 18 and older. Additional information about the vaginal ring in girls under age 18, particularly about its safety, would be required before regulatory bodies would consider expanding approval to include a younger population.

REACH is a Phase IIa study that is designed to fill important gaps in information about the safety and acceptability of the dapivirine ring and oral PrEP, including in girls as young as 16. REACH also seeks to understand what young women will need to help them to use these products. Each must be used consistently and regularly to be effective – daily for oral PrEP, and monthly for the ring – which has been a challenge for younger women in clinical trials.

“With PrEP being made available in many countries and the possibility that the ring will be approved, we want to see that these products can work for and be made available to women and girls of all ages at risk of HIV acquisition, who both need and deserve methods of protection that are in their control,” noted Lulu Nair, MBChB, MPH, protocol chair of the REACH study, who is clinical research site leader at the Desmond Tutu HIV Centre (DTHC), University of Cape Town, in Cape Town, South Africa.

REACH will enroll 300 young women and girls ages 16 to 21 at five MTN-affiliated clinical research sites in Kenya, South Africa, Uganda and Zimbabwe. Two of the sites have begun the study: the Makerere University-Johns Hopkins University Research Collaboration in Kampala, Uganda, where the first participant was enrolled, and the University of Zimbabwe College of Health Sciences Spilhaus Clinical Research Site in Harare.

All participants in REACH will use oral PrEP and the dapivirine ring, each for six months. After experiencing both approaches, participants will have a choice of using either the ring or PrEP – or neither – for an additional six months. REACH is expected to take about three years to conduct, with results anticipated in late 2022 or early 2023.

MTN researchers have already conducted a safety study of the dapivirine ring in the United States that enrolled 96 girls ages 15-17 who were randomly assigned to use the dapivirine ring or a placebo ring for a month at a time for a total of six months. Results of this study, referred to as MTN-023 /IPM 030, were reported in 2017 and found the ring was well-tolerated and acceptable. Adherence was also high – 95 percent of the rings returned after use had drug levels indicating consistent use during the previous month.

The dapivirine ring was well-tolerated and reduced the risk of HIV in two Phase III trials that together enrolled more than 4,500 women ages 18-45 from four African countries – ASPIRE , which was conducted by the MTN, and The Ring Study, led by the International Partnership for Microbicides (IPM), a non-profit organization that developed the dapivirine ring and is seeking its regulatory approval.

Yet, in ASPIRE, the dapivirine ring was not effective among younger women ages 18-21, who used the monthly ring least regularly. Similar results were seen among 18- to 21-year-old women in The Ring Study. Likewise, in studies with oral PrEP, it has been the younger participants who have struggled most with a daily pill-taking regimen. Results of a study, called HPTN 082, expected later this year, will shed additional light about PrEP use among girls ages 16-25 in South Africa and Zimbabwe.

As part of REACH, participants will receive extensive support and counseling focused on product adherence. They also will be encouraged to be open with study staff about any concerns or difficulties they may have.

“We have incorporated a number of supportive measures to help with adherence in REACH, but if girls aren’t willing or able to use the ring or PrEP, we want to understand why, so that we can learn what is needed to better support use,” explained Kenneth Ngure, Ph.D., M.P.H., associate professor and chair of the department of community health at Jomo Kenyatta University of Agriculture & Technology in Nairobi, Kenya, and REACH protocol co-chair. “At the same time, it’s important to recognize that these products won’t be for everyone, and the reasons why are just as important for us to understand.”

“Women need HIV prevention methods that are under their control, and their needs and preferences may change,” added Connie Celum, M.D., M.P.H., who is also a protocol co-chair, and professor of global health and medicine and director, International Clinical Research Center at the University of Washington in Seattle. “That’s why having different HIV prevention methods is so important, and why we have incorporated choice into the design of this study. It’s really quite exciting that we have come this far, to having PrEP, but also potentially the dapivirine ring.”

If approved, the ring could be available in some countries as early as 2020.

“Girls have told us that being able to protect themselves from HIV would be empowering, and that having choice would be especially empowering. They want and deserve to have control of their health, their lives and their destinies,” said Sharon Hillier, Ph.D., MTN principal investigator and professor and vice chair of the department of obstetrics, gynecology and reproductive sciences at the University of Pittsburgh School of Medicine and Magee-Womens Research Institute.

In addition to the sites in Uganda and Zimbabwe, REACH will be conducted in Kisumu, Kenya at the Kenya Medical Research Centre (KEMRI) Centre for Global Health; and in South Africa at the DTHF’s Emavundleni Research Centre in Cape Town and the Wits Reproductive Health and HIV Institute in Johannesburg.

According to UNAIDS, young women comprised 26 percent of new HIV infections in eastern and southern Africa in 2017, despite making up only 10 percent of the population. Many factors may contribute to HIV susceptibility in adolescent girls and young women, including gender-based violence, cultural and economic inequities and biological or hormonal changes.

As a global priority, young women and girls need safe and effective biomedical HIV prevention strategies for use throughout their lifespan, including during times of pregnancy and breastfeeding, when the risk of infection is estimated to be three to four times greater than when not pregnant or nursing. Similar to REACH, the MTN is planning studies of the monthly dapivirine ring and oral PrEP in pregnant women (MTN-042, or the DELIVER Study) and breastfeeding women and infants (MTN-043, or B-Protected).


Tagged with:

About author

Related Articles